UGT1A4 is a UDP-glucuronosyltransferase enzyme localized to the endoplasmic reticulum that catalyzes glucuronidation of diverse substrates including drugs, vitamins, and bile acids. Primary substrates include tertiary amines (imipramine, trifluoperazine, antipsychotics, anticonvulsants), vitamin D metabolites (25-hydroxyvitamin D3), and chenodeoxycholic acid 123. UGT1A4 functions through heterodimerization with other UGT1A isoforms, with coexpression of UGT1A1 and UGT1A6 modulating its catalytic activity in complex, substrate-dependent patterns 4. The enzyme exhibits significant genetic polymorphism; the UGT1A4*3 variant (Lys48Val) shows enhanced glucuronidation activity and influences drug metabolism and clinical efficacy 15. Functionally, UGT1A4-mediated glucuronidation is critical for clearance of lamotrigine and olanzapine, with genetic variants affecting serum concentrations and therapeutic responses 56. Additionally, UGT1A4 regulates bile acid homeostasis; microbiota-derived indole-3-carbinol represses UGT1A4 transcription to reduce pathogenic chenodeoxycholic acid glucuronidation, preventing bile acid-induced diarrhea 3. Emerging evidence suggests polygenetic influences on dexmedetomidine pharmacokinetics, though individual UGT1A4 polymorphism correlation remains weak 7. The enzyme is inducible by rifampin and other pregnane X receptor agonists, providing therapeutic opportunities for personalized drug dosing.